Guizhou Yibai Pharmaceutical vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Guizhou Yibai Pharmaceutical Co Ltd (600594.CG)

Q3 202614 Jul – 21 Aug 2026

▼3▲1

Yibai's losses widen as main products slump and regulators fine it again

First-half loss balloons on 30% revenue drop Yibai's main products sold far less, cutting revenue about 30% and pushing the first-half net loss to roughly 80 million yuan, much wider than last year's 20 million yuan loss. Even after cutting costs 26%, spending still exceeded sales, so the core business is shrinking and losing money.
The widening loss and falling sales are the central force dragging the stock down.
Regulator fines 700,000 yuan over cough syrup quality Guizhou's drug regulator fined Yibai 700,000 yuan for failing manufacturing quality standards on children's cough syrup, including skipped ingredient tests and missing records. The company says this follows its earlier 2025 suspension and no new violations occurred, but it adds to a record of repeated quality problems.
The fine is a fresh regulatory penalty that reinforces quality and compliance risk.
Two-and-a-half years of losses top 700 million yuan With 2024, 2025 and first-half 2026 all negative, cumulative losses now exceed 700 million yuan. Research spending has fallen five years straight, from 136 million yuan in 2021 to 84 million in 2025, raising doubts about the pipeline needed to replace weak products.
It shows the losses are a long-running pattern, not a one-off, and future growth spending is being cut.
Buyback shares to be cancelled, lifting per-share value Yibai disclosed it will change the purpose of its share buyback to cancellation and reduce registered capital. Cancelling bought-back shares shrinks the number of shares outstanding, which can modestly raise earnings per share and signals some shareholder-friendly intent, though it does not fix the weak business.
It is the one clearly supportive capital action in the period, offering a small counterweight to the losses.

August 202614 Jul – 21 Aug 2026

▼3▲1

Yibai's losses widen as main products slump and regulators fine it again

First-half loss balloons on 30% revenue drop Yibai's main products sold far less, cutting revenue about 30% and pushing the first-half net loss to roughly 80 million yuan, much wider than last year's 20 million yuan loss. Even after cutting costs 26%, spending still exceeded sales, so the core business is shrinking and losing money.
The widening loss and falling sales are the central force dragging the stock down.
Regulator fines 700,000 yuan over cough syrup quality Guizhou's drug regulator fined Yibai 700,000 yuan for failing manufacturing quality standards on children's cough syrup, including skipped ingredient tests and missing records. The company says this follows its earlier 2025 suspension and no new violations occurred, but it adds to a record of repeated quality problems.
The fine is a fresh regulatory penalty that reinforces quality and compliance risk.
Two-and-a-half years of losses top 700 million yuan With 2024, 2025 and first-half 2026 all negative, cumulative losses now exceed 700 million yuan. Research spending has fallen five years straight, from 136 million yuan in 2021 to 84 million in 2025, raising doubts about the pipeline needed to replace weak products.
It shows the losses are a long-running pattern, not a one-off, and future growth spending is being cut.
Buyback shares to be cancelled, lifting per-share value Yibai disclosed it will change the purpose of its share buyback to cancellation and reduce registered capital. Cancelling bought-back shares shrinks the number of shares outstanding, which can modestly raise earnings per share and signals some shareholder-friendly intent, though it does not fix the weak business.
It is the one clearly supportive capital action in the period, offering a small counterweight to the losses.

Latest14 Jul – 21 Aug 2026

▼3▲1

Yibai's losses widen as main products slump and regulators fine it again

First-half loss balloons on 30% revenue drop Yibai's main products sold far less, cutting revenue about 30% and pushing the first-half net loss to roughly 80 million yuan, much wider than last year's 20 million yuan loss. Even after cutting costs 26%, spending still exceeded sales, so the core business is shrinking and losing money.
The widening loss and falling sales are the central force dragging the stock down.
Regulator fines 700,000 yuan over cough syrup quality Guizhou's drug regulator fined Yibai 700,000 yuan for failing manufacturing quality standards on children's cough syrup, including skipped ingredient tests and missing records. The company says this follows its earlier 2025 suspension and no new violations occurred, but it adds to a record of repeated quality problems.
The fine is a fresh regulatory penalty that reinforces quality and compliance risk.
Two-and-a-half years of losses top 700 million yuan With 2024, 2025 and first-half 2026 all negative, cumulative losses now exceed 700 million yuan. Research spending has fallen five years straight, from 136 million yuan in 2021 to 84 million in 2025, raising doubts about the pipeline needed to replace weak products.
It shows the losses are a long-running pattern, not a one-off, and future growth spending is being cut.
Buyback shares to be cancelled, lifting per-share value Yibai disclosed it will change the purpose of its share buyback to cancellation and reduce registered capital. Cancelling bought-back shares shrinks the number of shares outstanding, which can modestly raise earnings per share and signals some shareholder-friendly intent, though it does not fix the weak business.
It is the one clearly supportive capital action in the period, offering a small counterweight to the losses.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

September 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

Latest27 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.